Vertex Pharmaceuticals (NASDAQ:VRTX) is recommended as a low volatility stock with strong growth potential by Bank of America Securities analyst Tazeen Ahmad, citing steady revenue growth in cystic fibrosis treatments like Alyftrek and Trikafta.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing